UK and Saudi Arabia Sign Veterinary Medicines Agreement to Strengthen Animal Health and Food Safety

FILE PHOTO

The United Kingdom and Saudi Arabia have signed a new agreement to strengthen cooperation on veterinary medicines, animal health and the growing global threat of antimicrobial resistance.

The Memorandum of Understanding (MoU), signed between the UK’s Veterinary Medicines Directorate (VMD) and the Saudi Food and Drug Authority (SFDA), will allow regulators in both countries to share scientific expertise, exchange regulatory information and improve oversight of medicines used to treat animals.

The agreement was signed in London during the DIA-MHRA Global Summit, an international gathering focused on improving cooperation between health regulators and supporting safer medical innovation.

Dr Hisham S. Aljadhey, Chief Executive Officer of the Saudi Food and Drug Authority, signed the agreement alongside Abigail Seager, Chief Executive Officer of the UK’s Veterinary Medicines Directorate.

Although the agreement focuses on veterinary medicines, its wider significance extends beyond animal healthcare. The way medicines are manufactured, approved and used in animals can have important consequences for food production, public health and efforts to prevent antibiotic resistance.

Both countries hope the partnership will strengthen their regulatory systems while helping ensure that veterinary medicines remain safe, effective and available when needed.

What is the new UK-Saudi veterinary medicines agreement?

The agreement establishes a formal framework for cooperation between the two national regulators responsible for overseeing veterinary medicines.

In the UK, the Veterinary Medicines Directorate regulates veterinary medicinal products and works to protect animal health, human health and the environment.

Saudi Arabia’s Food and Drug Authority oversees a broader range of regulated products, including veterinary medicines.

Under the new arrangement, both organisations will exchange information about veterinary medicine regulation, product availability, scientific assessments and the requirements companies must meet when seeking regulatory approval.

The partnership will also support the sharing of specialist knowledge through training programmes and exchanges involving experts and consultants.

This cooperation is intended to help both regulators learn from each other’s experience and strengthen their ability to respond to emerging challenges.

However, the signing of an MoU does not mean that veterinary medicines approved in one country will automatically become authorised for use in the other.

Each country will continue to apply its own relevant legal and regulatory requirements.

UK and Saudi regulators agree to share scientific expertise

One of the main objectives of the partnership is to improve access to scientific and technical knowledge.

Veterinary medicine regulation involves assessing whether products meet appropriate standards for quality, safety and effectiveness before they can be placed on the market.

Regulators must also monitor medicines after approval to identify potential safety concerns and ensure manufacturers continue to meet the required standards.

By exchanging assessment reports and information about regulatory requirements, the VMD and SFDA hope to strengthen the evidence available to support their work.

The agreement also provides opportunities for technical training and professional development.

Specialists from both organisations may be able to share experience in laboratory testing, product evaluation, manufacturing oversight and regulatory decision-making.

Such cooperation can be particularly valuable when authorities face similar scientific challenges or need to understand developments in veterinary pharmaceutical technology.

Why the agreement matters for animal and public health

Veterinary medicines play an essential role in protecting the health and welfare of animals, including pets, livestock and animals involved in food production.

Farmers and veterinary professionals rely on appropriately regulated medicines to prevent and treat diseases that can affect animal wellbeing and agricultural productivity.

However, veterinary medicines must be carefully assessed because their use can also have consequences for humans and the wider environment.

For example, medicines administered to food-producing animals may require controls to ensure that residues in meat, milk, eggs and other animal-derived products remain within permitted safety limits.

Regulators also need to consider how medicines are used, stored, manufactured and monitored after they reach the market.

Strong regulatory oversight helps reduce the risk of unsafe, ineffective or poor-quality products entering the supply chain.

The UK-Saudi agreement is intended to strengthen this work through closer cooperation, rather than replacing the existing systems responsible for protecting consumers and animals.

Tackling antimicrobial resistance is a major priority

A particularly important element of the agreement is cooperation on antimicrobial resistance, commonly known as AMR.

Antimicrobial resistance develops when microorganisms such as bacteria evolve in ways that allow them to survive medicines previously used to treat infections.

Antibiotic resistance is one of the most significant forms of AMR and presents a growing challenge to healthcare systems around the world.

The problem affects both human and animal health because resistant bacteria can spread between people, animals and the environment through different routes.

Inappropriate or unnecessary use of antibiotics can contribute to the development and spread of resistance.

Veterinary regulators therefore have an important role in promoting responsible antibiotic use and monitoring medicines intended for animals.

The VMD and SFDA have identified antimicrobial resistance as an area in which greater scientific cooperation could be beneficial.

By sharing information about regulatory policies, surveillance and medicine use, both organisations may be better positioned to respond to emerging risks.

However, the announcement does not establish a new joint antibiotic restriction or introduce immediate changes to prescribing rules for farmers and veterinary professionals.

What antimicrobial resistance means for food safety

Antimicrobial resistance is often discussed in relation to hospitals and human medicine, but its effects can also be connected to agriculture and food production.

Antibiotics are sometimes needed to treat bacterial infections in livestock and other animals.

When these medicines are used inappropriately, they can contribute to the selection of resistant bacteria.

Some resistant bacteria may spread through direct contact with animals, contaminated environments or parts of the food chain.

This is why international health organisations promote a One Health approach, recognising that human health, animal health and environmental health are closely connected.

For consumers, effective veterinary medicine regulation contributes to confidence that animal-derived food products are produced under appropriate health and safety controls.

It is important, however, to distinguish between antimicrobial resistance and veterinary medicine residues in food. These are related public health concerns, but they are not the same issue and require different monitoring and control measures.

The new agreement creates an opportunity for the UK and Saudi Arabia to share regulatory experience in addressing both the safe use of veterinary products and wider animal health risks.

Agreement covers laboratory testing and medicine safety monitoring

The partnership also includes cooperation on laboratory testing standards and the monitoring of veterinary medicines before and after they enter the market.

Before a veterinary medicine is authorised, regulators may assess evidence relating to its quality, safety and effectiveness.

Depending on the product, this can include manufacturing information, laboratory data and studies examining its use in animals.

After approval, monitoring remains important because additional information about a medicine’s performance or potential adverse effects may emerge during wider use.

The agreement will support exchanges of knowledge about these regulatory activities, including pre-marketing assessments and post-marketing surveillance.

Both authorities will also discuss market compliance and the regulation of manufacturers.

This could help improve understanding of how different regulatory systems identify and respond to products that fail to meet required standards.

The announcement does not specify any immediate enforcement operation or joint inspection programme, but it establishes a framework through which future cooperation can develop.

Could the agreement improve veterinary medicine availability?

Another area covered by the MoU is the availability of veterinary medicines.

Access to appropriate medicines is important for veterinarians, livestock producers and animal owners.

Shortages or limited availability can create difficulties when animals require treatment, particularly where suitable alternatives are not readily accessible.

By exchanging information about medicine availability and regulatory processes, the two authorities may be able to improve their understanding of shared challenges.

This could support future discussions about regulatory approaches and supply-related concerns.

However, the agreement does not guarantee lower veterinary medicine prices, immediate access to additional products or automatic recognition of approvals between the two countries.

Any changes affecting product availability would depend on subsequent regulatory decisions, market conditions and the actions of manufacturers.

UK and Saudi Arabia strengthen international regulatory cooperation

The agreement was signed on the sidelines of the DIA-MHRA Global Summit, which brought together international regulators, researchers and industry representatives in London.

The event focused on how cooperation between countries can support innovation while maintaining strong standards for health-related products.

The veterinary medicines partnership reflects a wider recognition that regulatory challenges increasingly cross national borders.

Medicine supply chains, scientific research, manufacturing technologies and antimicrobial resistance all involve issues that cannot always be addressed effectively by one country acting alone.

Dr Hisham S. Aljadhey welcomed the agreement as a framework for regulatory collaboration, technical capacity building and information exchange.

He said the partnership would strengthen the two countries’ ability to protect animal health and support the safety, quality and availability of veterinary products.

Abigail Seager also emphasised the importance of cooperation between veterinary medicine regulators.

She said the agreement would allow both countries to share scientific knowledge and learn from each other’s regulatory experience, including their approaches to antimicrobial resistance.

What happens next after the agreement?

The signing of the MoU establishes the basis for future cooperation between the VMD and SFDA.

The organisations are expected to use the agreement to exchange information, discuss regulatory practices and support technical learning.

Areas of cooperation include medicine assessments, laboratory standards, manufacturer oversight, market surveillance and antimicrobial resistance.

However, the announcement does not provide a timetable for individual projects, specify a funding commitment or identify particular medicines that will be assessed jointly.

The practical impact will become clearer as both regulators develop activities under the agreement.

For veterinary professionals and businesses, the main immediate development is the establishment of a formal relationship that could support stronger regulatory cooperation over time.

Existing UK rules governing veterinary medicines remain in place.

What the UK-Saudi agreement means for Nigerian veterinary professionals and food businesses in Britain

For Nigerians living in the UK, this agreement may appear to be a specialist development affecting veterinary regulators. However, it has practical relevance for Nigerian-trained veterinarians, agricultural professionals, food business owners and entrepreneurs involved in animal-related industries.

Nigerian professionals working in veterinary medicine, animal health research, pharmaceutical manufacturing or food safety may find that closer international regulatory cooperation creates opportunities to develop specialist knowledge.

For example, a Nigerian-trained veterinarian pursuing a career in Britain may benefit from understanding how the UK regulates veterinary medicines, monitors antibiotic use and applies safety standards to products intended for livestock and companion animals.

However, the agreement does not change the professional registration requirements for overseas-qualified veterinarians. Those seeking to practise veterinary surgery in the UK must still meet the applicable requirements of the Royal College of Veterinary Surgeons.

The announcement is also relevant to Nigerians operating food businesses in Britain, particularly those involved in meat products, frozen foods, catering and specialist grocery retail.

Food safety does not begin when a product reaches a supermarket or restaurant. It also depends on animal health, responsible medicine use and controls throughout the production and supply chain.

For Nigerian-owned restaurants and African food shops sourcing meat or other animal-derived products in the UK, the agreement reinforces the importance of buying from legitimate suppliers and maintaining appropriate food safety records.

However, it does not introduce a new import exemption or automatically simplify the rules for bringing meat, fish or other animal products from Nigeria into Britain.

Those activities remain subject to the relevant UK import, food safety and border requirements.

There is also a wider opportunity for Nigerian researchers and scientists working in Britain.

Antimicrobial resistance is a significant public health challenge in both the UK and Nigeria, and research into responsible antibiotic use can benefit from expertise across human medicine, veterinary medicine, agriculture and environmental science.

Nigerian professionals with experience in microbiology, laboratory testing, epidemiology and pharmaceutical quality assurance may find the agreement relevant to their wider fields of work, even though it does not establish a dedicated employment or research programme.

For Nigerians with an interest in agribusiness, the announcement highlights why modern livestock production increasingly requires more than access to feed, land and markets.

Understanding disease prevention, veterinary medicine standards and antibiotic stewardship is essential for protecting animal health and maintaining consumer confidence.

At Chijos News, the most important connection for the Nigerian diaspora is how international animal health standards influence the food businesses, scientific careers and agricultural investments that link Britain with other markets.

A Nigerian food entrepreneur in London sourcing meat for a catering business, a veterinary scientist in Manchester studying antibiotic resistance or an agricultural investor considering livestock production in Nigeria may approach the issue from different perspectives. Yet all three depend, in different ways, on reliable animal health systems and the responsible use of veterinary medicines.

The agreement between the UK and Saudi Arabia will not directly rewrite Nigeria’s veterinary regulations or create new trading rights for Nigerian businesses. What it does demonstrate is the growing importance governments place on scientific cooperation, medicine quality and the prevention of antimicrobial resistance.

For Nigerian professionals and entrepreneurs in Britain, those developments are worth following because expertise in animal health, food safety and pharmaceutical regulation is becoming increasingly important across international supply chains.

The longer-term value of the partnership will depend on whether the two regulators turn their commitment into meaningful information sharing, improved oversight and practical progress against threats such as antibiotic resistance.

Related posts

UK Flu Warning: Only 37% of Toddlers Vaccinated as Cases Rise Ahead of Christmas

UK Launches AdvanceGxP to Speed Up AI-Powered and Personalised Medicine Manufacturing

UK Launches Women’s Health Programme After Study Finds Pregnant Women Included in Just 1.1% of Clinical Trials